Unknown Kentucky biotech Bexion tests new glioma med on first patients. Yes, it’s the same cancer Sen. McCain is fighting, and Round B funding is still open.

The News: Bexion Pharmaceuticals burst out of the shadows of near total obscurity last week as its investigational cancer treatment, BXQ-350, grabbed plenty of mainstream media coverage as a potential game-changer. BXQ-350 is… Read more »

Move over, Nasdaq: BeiGene’s mammoth IPO in Hong Kong sends message to biotech startups.

The News: Nasdaq-listed Chinese biotech BeiGene Ltd. (Beijing) has raised an astounding $903 million after pricing its secondary listing in Hong Kong–the first under new exchange rules–near the top of… Read more »

Forget about Biogen/Eisai’s promising new drug for Alzheimer’s; Study says aggressive blood-pressure treatment with existing meds reduces dementia/AD risk.

The News: After decades of prominent failures, hope arose for a drug to slow the progression of Alzheimer’s disease (AD). After heightening expectations recently, Eisai Co. Ltd. (Tokyo) and Biogen… Read more »

With a frenzy of popping corks and champagne toasts, Sangamo bags French biotech TxCell as Europe’s CAR T-cell science expanding into autoimmune disease. SGMA is a buy.

The News: Sangamo Therapeutics Inc. (Richmond CA) has acquired TxCell SA (Valbonne FRA) with a view toward utilizing its chimeric antigen receptor (CAR) technology to prevent organ transplant rejections and treat… Read more »

Kite snags deal with Dutch biotech Gadeta to advance brand new CAR T-cell treatment for solid tumors.

The News: Kite Pharma Inc. (El Segundo CA) reportedly will support Gadeta BV (Utrecht NLD) in the development of a new type of CAR T-cell therapy that could be more… Read more »

Healthcare IPOs defy gravity and second law of thermodynamics with 8 new pricings last week and 2 new filings.

Well, here we are again, looking back at another massive round of biotech IPOs priced just last week, as the beat goes on and on and… My trusty, hand-held calculator… Read more »

Vertex says it would be NICE if England upped its offer for new CF drugs. Meanwhile, short lesson on how US could quickly lower its pharma prices, too.

The News: Vertex Pharma CEO Jeffrey Leiden’s move earlier this month to pressure England’s prime minister Theresa May on drug prices seems to have set some wheels in motion. After… Read more »

Tiny Swedish biotech not taking back seat to US in Alzheimer’s race. How to buy it.

The News: BioArctic AB, based in Stockholm, said it has clinical results showing its antibody treatment that targets amyloid plaques, a hallmark of Alzheimer’s disease, can slow the disease’s progression. The trial… Read more »

The growing link between blockchain and the safety of our genomic data; a primer.

The News: As the cost of sequencing an individual genome gets lower and more people have access to their genomic data, a question has arisen about data ownership. Namely, who… Read more »